|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The poly-(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib, have recently been approved for use in patients with metastatic breast cancer (BC) and germline BRCA 1 or 2 mutations due to improved progression-free survival compared to chemotherapy.
|
31823331 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, the PARP inhibitors olaparib and rucaparib were FDA approved for the treatment of metastatic breast cancer and recurrent ovarian cancer patients with mutations in BRCA1/2.
|
31575654 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We sequenced cfDNA of a hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) cohort with a high coverage to examine the prevalence and relevance of any detected variant. cfDNA of 44 MBC patients was isolated, followed by library construction using a customized targeted DNA panel with integrated unique molecular indices analyzing AKT1, AR, BRCA1, BRCA2, EGFR, ERCC4, ERBB2, ERBB3, ESR1, FGFR1, KRAS, MUC16, PIK3CA, PIK3R1, PTEN, PTGFR, and TGFB1.
|
31254045 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
|
30656571 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As no patients with BRCA1/2+ mutation died of metastatic breast cancer or recurrence during follow-up and review, overall survival could not be evaluated.
|
30973374 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician's choice (TPC) in patients with a germline BRCA1 and/or BRCA2 mutation (BRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC).
|
30689707 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusion:</b><i>BRCA1/2</i> mutation profiling to target olaparib use is not a cost-effective strategy for metastatic breast cancer.
|
31692405 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sensitivity to endocrine therapy of patients with estrogen receptor (ER)-positive metastatic breast cancer and germline <i>BRCA1/2</i> mutations is not yet fully elucidated.
|
31456944 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Poly(ADP-ribose) polymerase (PARP) inhibitors were recently approved for the treatment of patients with BRCA1 or BRCA2 germline pathogenic variants and metastatic breast cancer.
|
30789866 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Eligible patients ≥18 years with locally recurrent or metastatic breast cancer and a deleterious BRCA1/2 germline mutation were randomized 1 : 1 : 1 to VCP, VT, or placebo plus carboplatin/paclitaxel (PCP).
|
29045554 |
2018 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We summarize the clinical development of PARPi in breast cancer from bench to bedside, and discuss the results of recent phase 3 trials in patients with metastatic breast cancer (MBC) and germline mutations in BRCA1/2 (gBRCAm).
|
29884921 |
2018 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current randomized phase three trials of PARPi in metastatic breast cancer are limited to patients with documented BRCA1/2 mutations and no biomarker of PARPi beyond BRCA status is available.
|
28316110 |
2017 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Several clinical studies have investigated single agent therapy or combinations of both drugs, but no randomized clinical evidence exists for the superiority of carboplatin-olaparib versus standard of care therapy in patients with BRCA1- or BRCA2--mutated metastatic breast cancer.
|
27323902 |
2016 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Forty BRCA1/2 germline mutation carriers with MBC were included.
|
24692579 |
2014 |
|
Carcinoma breast stage IV
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A variant in the 3'UTR of BRCA1 is functional, leading to decreased BRCA1 expression, modest increased breast cancer risk, and most importantly, presentation with stage IV breast cancer, likely due to aggressive tumor biology.
|
24915755 |
2014 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of 195 women with MBC, 21 % (n = 41) were positive for BRCA1/2 mutations.
|
23370825 |
2013 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a phase II, open-label study, 20 patients with metastatic breast cancer who carried a mutation in BRCA1 were treated with cisplatin 75 mg/m2 intravenously every 3 weeks as part of a 21-day cycle for 6 cycles.
|
22817698 |
2012 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Response rates (RRs) to and progression-free survival (PFS) after taxane chemotherapy of 35 BRCA1-associated and 13 BRCA2-associated metastatic breast cancer patients were compared with those outcomes in 95 matched (1:2) sporadic patients.
|
21761396 |
2012 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
For BRCA1-associated patients, a nonsignificant trend for an increased OR (66% v 50%; P = .07), and a longer PFS (HR(mult), 0.79; P = .14) after first-line chemotherapy for metastatic breast cancer was observed, but not for OS.
|
19564533 |
2009 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.
|
18591931 |
2008 |